Loading…
Tristel's FY2025 results show a 23% surge in adjusted pre-tax profit to £10.1m, with 11% revenue growth and a 5% dividend boost. US expansion gains momentum.
This article covers information on Tristel PLC.
LON:TSTLTristel has turned in another tidy set of audited results for the year to 30 June 2025. Revenue rose 11% to £46.5m, adjusted pre-tax profit jumped 23% to £10.1m, and cash generation stayed robust. The balance sheet remains debt free, and the total cash and short-term investments stack finished at £12.8m.
The engine room is still medical device disinfection under the Tristel brand – 87% of sales – with the Cache surface disinfection range at 8%. The US story is gathering pace with FDA approvals in ultrasound and ophthalmology, early traction across c.200 health systems, and supportive clinical evidence. The dividend is up again, and management has set fresh multi-year targets that commit to double-digit growth and a 25%+ EBITDA margin.
| Revenue | £46.5m (+11%) |
| Gross margin | 81% (FY2024: 80%). Adjusted gross margin 84% |
| Adjusted pre-tax profit | £10.1m (+23%) |
| Reported pre-tax profit | £8.4m (+18%) |
| Adjusted EPS | 17.15p (FY2024: 15.34p) |
| Basic EPS | 13.92p (FY2024: 13.68p) |
| Adjusted EBITDA margin | 27.8% (FY2024: 26.0%) |
| Operating cash flow | £10.3m (FY2024: £10.9m) |
| Cash + short-term investments | £12.8m (FY2024: £11.8m) |
| Total dividend | 14.20p per share (+5%). Final 8.52p |
| ROCE | 22% |
Most of the top-line growth came from doing more, not charging more. Of the £4.5m revenue uplift, £3.8m was volume and £0.8m price. The average price increase was 2% (FY2024: 11%), which suggests underlying adoption is doing the heavy lifting now that the big pricing resets are behind them.
Gross margin ticked up to 81% thanks to mix and efficiencies. On an adjusted basis, gross margin was 84%. The insourcing of Trio Wipes Manufacturing delivered £0.8m net annual savings, which should continue to support margin resilience.
Adjusted figures exclude £0.4m of share-based payments and £1.4m of exceptional items tied to CEO/CFO succession. On a reported basis, pre-tax profit was £8.4m. Excluding those items, adjusted pre-tax profit was £10.1m – up 23% year on year. This is the number to compare operational performance year to year.
The effective tax rate rose as Patent Box benefits reduced. That held back statutory EPS growth a touch, but adjusted EPS still rose 12% to 17.15p.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
44 viewsLikes
No ratings yet
Last updated:
The Board is proposing a final dividend of 8.52p, taking the full-year payout to 14.20p – up 5%. Timings: ex-dividend 27 November 2025, record date 28 November, payment on 18 December 2025.
Cash generation remains a bright spot. Operating cash flow was £10.3m, and the Group ended the year with £8.6m cash and £4.2m in short-term investments. No debt, only lease liabilities. This supports ongoing investment and the progressive dividend policy.
FY2025 was Tristel’s first full commercial year in North America. Royalty income rose to £108k (FY2024: £74k) – still small in the context of the Group, but the groundwork looks solid:
Management reports engagement across approximately 200 health systems. The focus now is deepening adoption within these accounts to drive recurring consumables revenue. That is the crux: the US is a volume and repeat-purchase story, and the indicators are moving in the right direction.
Beyond ULT and OPH, Tristel launched VISICLEAN in September 2025 – a coloured manual cleaning technology designed to improve compliance by giving visible assurance that cleaning has been done properly. The company is also sharpening the Cache strategy on high-risk hospital environments where sporicidal performance matters most.
On software, the 3T digital platform gets a two-track push in FY2026 – 3T Lite for easier adoption at point-of-care and 3T Pro as a paid, recurring revenue product. Traceability and audit are increasingly non-negotiable in infection prevention; a software layer strengthens stickiness and data-led compliance.
Tristel continues to broaden geographically. Spain and India moved to direct operations, and Austria was added. The Middle East nearly doubled year-on-year and now contributes 4% of Group sales. Germany is benefiting from KRINKO guideline changes that endorse chlorine dioxide wipes for HLD.
One watch-out: concentration remains high in the UK. A single UK customer represented 26% of Group revenue, and 58% of Cache revenue came from one UK customer. It is not unusual in NHS-heavy businesses, but it is a risk to monitor.
Post period-end, Anna Wasyl joined as CFO. Exceptional items of £1.4m relate to outgoing CEO and CFO succession costs. The Group highlights strong diversity metrics and talent retention, which matters for scaling a specialist portfolio globally.
The Board remains confident, and the plan is clear: scale in North America, deepen penetration in existing markets, grow the portfolio, and monetise the 3T platform. The near-term catalysts are adoption curves for ULT and OPH in the US, early traction for VISICLEAN, and continued mix-led margin support.
If Tristel can turn its US pipeline into recurring consumables revenue while maintaining 25%+ EBITDA margins, the compounding effect could be meaningful. The ingredients – regulatory approvals, clinical evidence, and a partner with reach – are in place. Execution is now the lever.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.